The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Opinion|Videos|January 31, 2025 (Updated: January 31, 2025)
Clinical Insights on Use of CAR-T Therapy
This segment highlights clinical experiences with ide-cel in the second-line setting, focusing on observed improvements in efficacy and quality of life, as well as challenges in administration
Advertisement
Video content above is prompted by the following:
- Can you share your experience with using ide-cel in the second-line setting?
- What improvements in efficacy and quality of life have you observed?
- What challenges have you faced in administering this treatment?
Advertisement
Related to this article
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Matthew Matasar, MD, reflected on how quickly oncology has moved from skepticism to nimble adoption of AI, and what he expects from the field going forward.
Advertisement
Advertisement
Trending on CancerNetwork
1
Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast Cancer
2
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
3
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
4
How Does Azacitidine/Venetoclax Impact Hospital Burden in AML?
5